Biotech Values

[DewDiligence]

Servier, NVS ink oncology collaboration focused on BCL-2:

http://www.servier.com/content/servier-enters-global-collaboration-agreement-development-and-commercialization-new-drugs

Servier today announced that they have signed a strategic global collaboration agreement with Novartis to develop and commercialize a series of novel drugs candidates issued from the Servier research programs partnered with Vernalis in oncology which are targeting the apoptosis regulation pathways.

The collaboration covers the worldwide co-development of BCL-2 selective inhibitor candidates that are now entering into clinical development… Servier will remain responsible for research activities and will share responsibilities with Novartis to conduct a clinical development program aimed at moving swiftly to a first indication for the benefit of patients. Commercialization rights to products arising from the collaboration will be allocated between the parties on a geographic basis.

There’s no mention of an up-front payment, but that doesn’t mean there isn’t one; as a private company, Servier discloses less information about dealmaking than a typical public company.